Úvod Laboratorní plasty Zkumavky Microcentrifuge Tube 1.5 ml Microcentrifuge Tube SALSA MLPA P105 Glioma-2 probemix - 50 reactions

SALSA MLPA P105 Glioma-2 probemix - 50 reactions

application: Glioma, malignant
region: EGFR, TP53, PTEN + various other Detailní informace

Cena s DPH € 573.54
Cena bez DPH € 474.00
 50 react
Dostupnost Skladem
Kód produktu P105-050R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P105 Glioma-2 probemix - 50 reactions

P105-050R SALSA MLPA P105 Glioma-2 probemix – 50 rxn

Gliomas are the most common primary brain tumours and account for one third of central nervous system (CNS) tumours. Gliomas comprise a very heterogeneous group of CNS neoplasms derived from glial cells. There are several oncogenes and tumour suppressor genes, which have been shown to undergo copy number changes in these tumours. Somatic mutations, disruptions, or copy number aberrations in three critical signalling pathways, a) RTK/PI3K pathway (involving e.g. EGFR, PDGFRA and PTEN genes), b) p53 pathway (involving e.g. CDKN2A, MDM2 and TP53 genes) and c) RB pathway (involving e.g. CDKN2A and CDK4 genes), are suggested to contribute to the development of glioma (TCGA, 2008. Nature. 455:1061-8).

Epidermal growth factor receptor (EGFR) and its ligands are cell signalling molecules involved in diverse cellular functions. These include cell proliferation, differentiation, motility, and survival, and tissue development. Glioblastomas often express EGFRvIII, a  constitutively active genomic deletion variant of EGFR which is characterised by deletions of exons 2-7 of the EGFR gene (Humphrey PA et al. 1990. PNAS 87:4207-11; Sugawa N et al. 1990. PNAS 87:8602-6).

This SALSA® MLPA® probemix can be used to determine aberrant copy number of EGFR (7p11.2), PTEN (10q23.31), CDKN2A (9p21.3), TP53 (17p13.1), PDGFRA (4q12), NFKBIA (14q13.2) and CDK4-MIR26A2-MDM2 (12q14-q15) genes. This probemix also allows detection of deletions of EGFR that result in EGFRvIII. In addition, 12 reference probes have been included in this probemix, detecting several different autosomal chromosomal locations, which are relatively quiet in gliomas.

This SALSA® MLPA® probemix is designed to detect copy number changes of one or more sequences in the above mentioned genes in a DNA sample. Heterozygous deletions of recognition sequences should give a 35-50% reduced relative peak height of the amplification product of that probe. Note that a mutation or polymorphism (e.g. SNP) in the sequence detected by a probe can also cause a reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings.

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail

Vaše osobní údaje nejsou nikde zveřejňovány a splňují požadavky GDPR.